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Abstract
Background: Transarterial chemoembolization (TACE) and sorafenib are the therapeutic standard for intermediate
and advanced stage hepatocellular carcinoma (HCC) patients respectively. High costs with adverse events (AE)
of sorafenib might limit sorafenib dosage, further affecting therapeutic response. To attain greatest benefit, we
evaluated the efficacy of different doses and effect of TACE during and after sorafenib discontinuation in patients
representing Child-Pugh Classification Class A with venous or extra-hepatic invasion.
Methods: A total 156 patients met the criteria and were divided into Groups I (n = 52) accepting 800 mg/day; II
(n = 58) accepting 800 mg/day and reduced to 400 mg/day owing to AE; and III (n = 46) accepting 400 mg/day.
TACE was performed during and after sorafenib discontinuation and therapeutic response bimonthly to
four-monthly was rated thereafter.
Results: Median duration of sorafenib treatment and patients’ survival were 4.00 ± 0.45 and 7.50 ± 1.44 months
in all cases; 2.50 ± 0.90 and 5.00 ± 1.10 months in Group I; 5.50 ± 1.27 and 16.50 ± 1.86 months in Group II;
4.00 ± 0.94 and 6.50 ± 2.49 months in Group III. Group II presented the best response and survival benefit
(p = 0.010 and p = 0.011 respectively). Child-Pugh Classification score 5 (Hazard Ratio = 0.492, p = 0.049), absent
AE (3.423, p = 0.015), tumor numbers ≤ 3 (0.313, p = 0.009), sorafenib duration ≤ 1 cycle (3.694, p = 0.004), and
absent TACE (3.197, p = 0.008) significantly correlated with patient survival. TACE benefit appeared in separate
and total cases during (p = 0.002, p = 0.595, p = 0.074, p = 0.002 respectively) and after discontinuation of
sorafenib administration (p = 0.001, p = 0.034, p = 0.647, p = 0.001 respectively).
Conclusions: Low-dosage sorafenib not only appeared tolerable and lowered economic pressure but also
provided satisfactory results. TACE benefited patient’s survival during and after sorafenib discontinuation.
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Background
Worldwide, more than 711,000 new hepatocellular car-
cinoma (HCC) patients are diagnosed annually; 679,000
eventually die [1]. Various diagnostic and therapeutic
modalities have been applied in clinical scenarios [2],
with over 50 % of HCC cases showing unresectable or
un-embolized condition [3]. Only palliative options are
available due to limitations of vascular invasion or extra-
hepatic metastases [3, 4].
Sorafenib (Nexavar, Bayer HealthCare Pharmaceuticals-
Onyx Pharmaceuticals) inhibits proliferation and
angiogenesis in tumors, promoting apoptosis [5, 6].
Anti-angiogenic function is via inhibition of VEGFR-
2-PDGFR- and Raf-kinase properties [5–7], signaling
pathways identified as a close rationale in HCC
study and providing survival benefits in advanced
HCC [Barcelona Clinic Liver Cancer (BCLC) stage
C] [7–12]. Limitations affect patients treated with
sorafenib in clinical scenarios: e.g., high cost raising
economic pressure [13], while severe adverse events
(AE) (26–88 %) might limit sorafenib dosage and im-
pair therapeutic response, as well as high tumor re-
currence with single agent [8, 9, 14, 15]. Therefore,
combination therapy provided lesser dose of sorafe-
nib to obtain better response for both in vitro and
in vivo models [16]. In clinical settings, transarterial
chemoembolization (TACE) is the current standard
therapy for intermediate stage HCC (BCLC stage B)
and an earlier study indicated combination of TACE
with sorafenib as being more effective than TACE or
sorafenib monotherapy for unresectable HCC [17];
but no data is reported on the exploration of the ef-
fect of different sorafenib dosage with subsequent
TACE during or after discontinued sorafenib.
To attain the greatest benefit in clinical scenarios, we
assessed two points in this study. First, investigating the
relation of different therapeutic doses (initially 400 or
800 mg per day) with efficacy in unresectable HCC
patients with compensated liver disease (Child-Pugh
Classification Class A [18]) and venous invasion or
extra-hepatic metastases. Furthermore, evaluating the ef-
fect of TACE during and after sorafenib discontinuation.




According to the standard of Taiwan's National Health
Insurance Agency, sorafenib was approved for HCC
patients exhibiting Child-Pugh Classification Class A
(score 5 or 6) with venous invasion or extra-hepatic me-
tastases. Excluding HCC patients not up to the standard
during the period of May 2009 to June 2013, 156 cases
(HCC-total group) met the criteria and accepted
sorafenib therapy at China Medical University Hospital,
Taichung, Taiwan; and their response and survival re-
sults were recorded until May 2014. After reviewing
their therapeutic dosage between May 2009 and June
2013, patients were divided into three groups: Group I
for patients accepting 400 mg sorafenib twice daily;
Group II for patients accepting initially 400 mg sorafenib
twice daily with reduction to 400 mg once daily owing
to intolerable AE; and Group III for patients accepting
400 mg sorafenib daily (Fig. 1). Dose reduction in Group
II depended on their tolerance to sorafenib inducing AE
(hand-foot skin reaction, uncontrollable hypertension, or
diarrhea) rated by the National Cancer Institute (NCI)
Common Terminology Criteria for Adverse Events
(CTCAE) [19]. The management of AE included cortico-
steroid cream and painkiller pill for hand-foot skin reac-
tion, anti-hypertension agent for hypertensive patients,
as well as loperamide for diarrhea.
Evaluation of therapeutic response during sorafenib
therapy
All treated patients were according to the standard of
Taiwan's National Health Insurance Agency and hospital
protocol. For each visit while undergoing sorafenib treat-
ment, patients accepted detailed history and physical
examination every four weeks. In addition, biochemical
examination including Child-Pugh Classification score,
serum AFP, renal function, and contrast-enhanced
tomography (CT) were performed on those beginning
sorafenib and followed up bimonthly to 4-month there-
after according to therapeutic dosage (defined as one
cycle) to rate therapeutic response by Response Evalu-
ation Criteria in Solid Tumors criteria (RECIST); only
those with better response (complete response [CR], par-
tial response [PR], or stable disease [SD]) could continue
sorafenib treatment [20].
Procedure and effect comparisons of transarterial
chemoembolization
In our hospital, TACE proceeds via the trans-femoral
route, with arteries feeding tumors identified by angiog-
raphy and then emulsion of lipiodol (10 mL) and
adriamycin (20 mg) were injected, followed by
embolization with absorbable particles (gelatin foam).
After embolization, more angiography was used to assess
extent of vascular occlusion and flow in other arteries.
Effect of TACE was evaluated during and after discon-
tinuation of sorafenib administration in separate groups,
with follow-up time of either patient death or at least six
months after sorafenib discontinuation due to poor
therapeutic response. Patients treated with TACE were
according to the standard of BCLC System and our hos-
pital for intra-hepatic tumor.
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Serological markers and liver biochemical assay
methodology
Commercial enzyme immunoassay rated HBV markers
(HBsAg, HBeAg, anti-HBe) (AxSYM, Abbott, North
Chicago, IL) and anti-HCV antibody (Abbott HCV EIA
2.0; Abbott Laboratories). An autoanalyzer (TBA-30FR,
Toshiba, Tokyo, Japan) gauged serum albumin, bilirubin,
alpha-fetoprotein (AFP), aspartate transaminase (AST),
alanine Transaminase (ALT), alkaline phosphatase
(Alk-p), creatinine (Cr), International Normalize Ratio
(INR), and hematological count (WBC: white blood cell;
Hb, hemoglobin; platelet).
Statistical analysis
All statistical analyses were performed using SPSS 17.0
(SPSS, Chicago, USA). Baseline data were expressed as
mean ± standard deviation, with correlation between
continuous variables assessed by Student t-test or Fisher
exact test. In univariate survival analysis, the median
survival times were calculated according to the
Kaplan-Meier method. All variables significant in
univariate analysis were entered into the multivariate
model according to Cox proportional hazard regres-
sion. All statistical tests were two-tailed, P-value ≤
0.05 defined as significant.
Results
General distribution of overall and separate
hepatocellular carcinoma groups
Table 1 shows baseline characteristics of 156 HCC cases.
Median durations of sorafenib treatment and patients’
survival were 4.00 ± 0.45 months (95 % CI 3.13–
4.87 months) and 7.50 ± 1.44 months (95 % CI 4.67–
10.33 months) respectively. There were 57 patients with-
out and 99 with AE: e.g., hand-foot skin reaction (n = 53
cases; 45 in grade 1 and 2; 8 in grade 3), diarrhea (n = 24
cases; 19 in grade 1 and 2; 5 in grade 3), hypertension
(n = 5 cases; 4 in grade 1 and 2; 1 in grade 3), combin-
ation of hand-foot skin reaction and diarrhea (n = 17; 14
in grade 1 and 2; 3 in grade 3). No grade 4 or mortality
case was induced from AE. According to therapeutic
dosage, 52 cases belonged to Group I, 56 cases belonged
to Group II, and 46 cases belonged to Group III (Fig. 1).
No significant difference between the three groups
besides lower albumin (3.68 ± 0.51 versus 4.05 ±
0.42 g/dL, p < 0.001) with advanced age (64.50 ± 12.02
versus 58.75 ± 13.33 years, p = 0.028) in Group III
than Group I. In separate groups, median durations of so-
rafenib treatment and survival were 2.50 ± 0.90 months
(95 % CI 0.73–4.27 months) and 5.00 ± 1.10 months (95 %
CI 2.85–7.16 months) in Group I; 5.50 ± 1.27 months
(95 % CI 3.01–7.99 months) and 16.50 ± 1.86 months
(95 % CI 12.86–20.14 months) in Group II; 4.00 ±
0.94 months (95 % CI 2.16–5.84 months) and 6.50 ±
2.49 months (95 % CI 1.63–11.37 months) in Group III
respectively.
Survival analysis in overall and separate groups
In total cases, the significant factors including Child-Pugh
Classification score 5 (p = 0.015), absent AE (p < 0.001),
lower ALT (p = 0.036), lower AFP (p < 0.001), tumor size ≤
5 cm (p = 0.046), tumor numbers ≤ 3 (p = 0.001), sorafenib
duration ≤ 1 cycle (p < 0.001), and absent TACE (p =
0.031) affected patient’s survival. Of all significant vari-
ables, Child-Pugh Classification score 5 (Hazard Ratio =
0.492, p = 0.049), absent AE (Hazard Ratio = 3.423, p =
0.015), lower AFP (Hazard Ratio = 0.213, p = 0.003), tumor
numbers ≤ 3 (Hazard Ratio = 0.313, p = 0.009), sorafenib
duration ≤ 1 cycle (Hazard Ratio = 3.694, p = 0.004), and
absent TACE (Hazard Ratio = 3.197, p = 0.008) signifi-
cantly correlated with patient mortality (Table 2).
Among separate groups, absent AE (p = 0.008), lower
Fig. 1 Flow diagram showing the initial therapeutic dose and study aims
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AFP (p = 0.014), tumor numbers ≤ 3 (p = 0.032), and
sorafenib duration ≤ 1 cycle (p = 0.003) presented sig-
nificant difference affecting patient’s survival. Of all
significant variables, lower AFP (Hazard Ratio = 0.136,
p = 0.047) and sorafenib duration ≤ 1 cycle (Hazard
Ratio = 8.112, p = 0.040) played independent roles to
predict patient’s mortality in Group I. In Group II,
the factors including lower AFP (p = 0.043), sorafenib
duration ≤ 1 cycle (p = 0.002), and absent TACE (p =
0.041) presented significant difference affecting pa-
tient’s survival. Of all significant variables, sorafenib
duration ≤ 1 cycle (Hazard Ratio = 7.080, p = 0.014)
and absent TACE (Hazard Ratio = 6.742, p = 0.022)
played independent roles to predict patient’s mortality.
In Group III, lower albumin (p = 0.048) and tumor
numbers ≤ 3 (p = 0.023) presented significant differ-
ence affecting patient’s survival. Of all significant vari-
ables, lower albumin (Hazard Ratio = 5.989, p = 0.046)
and tumor numbers ≤ 3 (Hazard Ratio = 0.187, p =
0.025) played independent roles to predict patient’s
mortality.
Positive correlation between better sorafenib response
and higher survival
There was a positive correlation between sorafenib dur-
ation and survival time (r = 0.756, p < 0.001). Group II
showed the best sorafenib response and overall survival
among the three groups (p = 0.010 and p = 0.011 respect-
ively) (Fig. 2).
Table 1 Baseline characteristics of total and separate hepatocellular carcinoma groups treated with sorafenib
Demographics Total cases (n = 156) Group I (n = 52) Group II (n = 58) Group III (n = 46)
Age (yrs) (range) 61.04 ± 12.76 (32.00–88.00) 58.75 ± 13.33 (32.0–84.0) 60.36 ± 12.45 (32.0–88.0) 64.50 ± 12.02 (40.0–86.0)
Sex (Male) (%) 127 (81.41) 46 (88.5) 52 (89.66) 29 (63.04)
BMI (kgs/m2) (range) 22.69 ± 3.88(14.10–34.82) 23.05 ± 3.71 (15.24–34.82) 21.92 ± 3.48 (14.10–32.86) 23.26 ± 4.43 (15.56–33.75)
Cirrhosis (+) (%) 120 (76.92) 32 (61.5) 50 (86.21) 38 (82.61)
CPC, score 5 versus 6 (%) 81 (51.92) versus 75 (48.08) 30 (57.7) versus 22 (42.3) 31 (53.45) versus 27 (46.55) 20 (43.48) versus 26 (56.52)
Biochemical values
Albumin (g/dL) (range) 3.88 ± 0.50 (2.80–5.10) 4.05 ± 0.42 (3.20–4.80) 3.88 ± 0.51 (2.80–5.10) 3.68 ± 0.51 (2.80–4.70)
Bilirubin (mg/dL) (range) 1.02 ± 0.46 (0.19–2.41) 0.99 ± 0.41 (0.22–1.99) 1.03 ± 0.48 (0.19–2.29) 1.05 ± 0.51 (0.38–2.41)
INR (range) 1.14 ± 0.13 (0.89–1.63) 1.13 ± 0.12 (0.90–1.63) 1.15 ± 0.13 (0.90–1.48) 1.15 ± 0.15 (0.89–1.63)
































Cr (mg/dL) (range) 0.93 ± 0.35 (0.21–2.76) 0.90 ± 0.30 (0.40–2.10) 0.94 ± 0.32 (0.27–1.76) 0.95 ± 0.43 (0.21–2.76)
WBC (103/uL) (range) 6.90 ± 3.71 (1.70–22.62) 6.96 ± 3.33 (2.48–17.35) 6.79 ± 3.66 (1.70–19.00) 7.00 ± 4.23 (2.10–22.62)
Hb (gm/dL) (range) 12.48 ± 1.97 (7.90–17.10) 12.63 ± 1.98 (7.90–16.00) 12.64 ± 2.02 (7.90–17.10) 12.11 ± 1.89 (8.10–15.10)









B or C or B + C (+)
or NBNC (%)
80 (51.28) or 50 (32.05)
or 5 (3.21) or 21 (13.46)
30 (57.7) or 9 (17.3)
or 3 (5.8) or 10 (19.2)
33 (56.9) or 18 (31.03)
or 1 (1.72) or 6 (10.34)
17 (36.96) or 23 (50.0)
or 1 (2.17) or 5(10.87)
Tumor characters
Tumor size (>5 cm) (%) 74 (47.44) 27 (51.9) 25 (43.1) 22 (47.83)
Tumor number (>3) (%) 91 (58.33) 28 (53.8) 32 (55.17) 31 (67.39)
Intra-hepatic vein (+) (%) 61 (39.10) 23 (44.2) 18 (31.03) 20 (43.48)
Extra-hepatic metastases (%) 75 (48.08) 23 (44.2) 31 (53.45) 21 (45.65)
Mixed type (vein and metastases) 20 (12.82) 6 (11.5) 9 (15.52) 5 (10.87)
Abbreviations: CPC child-pugh classification, INR international normalize ratio, AST aspartate transaminase, ALT alanine transaminase, Alk-p alkaline phosphatase,
GGT gamma-glutamyltransferase, AFP alpha-fetoprotein, Cr creatinine, WBC white blood cell, Hb hemoglobin, B hepatitis B virus, C hepatitis C virus, B + C hepatitis
B and C virus, NBNC non-hepatitis B or C virus
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TACE increases survival during and after sorafenib
discontinuation
Over the study period, presence or absence of TACE
presented significant difference (p = 0.031) and signifi-
cantly correlated with patient mortality (Hazard Ratio =
3.197, p = 0.008) (Table 2). During the sorafenib period,
patients accepting TACE revealed lower mortality than
those without TACE, particularly in total patients (39/57
versus 75/99, p = 0.002) and Group I (14/21 versus 28/
31, p = 0.002) (Table 3). Patients accepting TACE had
younger age (57.54 ± 13.00 versus 63.06 ± 12.24 years,
p = 0.009) than those without TACE among HCC total
patients; lower AST (62.48 ± 37.92 versus 119.80 ±
124.85 IU/L, p = 0.024), higher albumin (4.20 ± 0.43
versus 3.95 ± 0.39 g/dL, p = 0.041), and lower BMI
(21.78 ± 3.77 versus 23.91 ± 3.47 kg/m2, p = 0.041) or
higher average dose (37.85 ± 6.89 versus 34.10 ±
4.61 mg/kg, p = 0.036) in Group I; lower Cr (0.83 ± 0.21
versus 1.00 ± 0.36 mg/dL, p = 0.022) and higher rate of
tumor numbers > 3 (16/21 versus 16/37, p = 0.027) in
Table 2 Cox regression of mortality in overall hepatocellular carcinoma patients. (N = 156)
Numbers P-value Hazard Ratio
(95 % CI)Univariate Multivariate
Demographics
Age (yrs), ≤65 vs. >65 100 vs. 56 0.613
Gender, Female vs. Male 29 vs. 127 0.863
BMI (kgs/m2), ≤22 (24) vs. >22 (24) 102 vs. 54 0.798
Average dose (mg/kg), ≤35 vs. >35 97 vs. 59 0.848
Cirrhosis, (-) vs. (+) 36 vs. 120 0.263
CPC, score 5 vs. 6 81 vs. 75 0.015* 0.049* 0.492 (0.213–1.137)
AE, (-) vs. (+) 57 vs. 99 <0.001* 0.015* 3.423 (1.274–9.199)
Biochemical values
Albumin (g/dL), ≤3.5 vs. >3.5 35 vs. 121 0.061
Bilirubin (mg/dL), ≤1.3 vs. > 1.3 118 vs. 38 0.466
INR, ≤1.2 vs. >1.2 116 vs. 40 0.321
AST (IU/L), ≤34 vs. >34 25 vs. 130 0.181
ALT (IU/L), ≤40 vs. >40 73 vs.83 0.036*
Alk-p (IU/L), ≤126 vs. >126 87 vs.39 0.051
AFP (ng/mL), ≤9 vs. > 9 34 vs. 122 <0.001* 0.003* 0.213 (0.078–0.583)
Creatinine (mg/dL), ≤1.3 vs. > 1.3 138 vs. 18 0.188
WBC (103/dL), ≤105 vs. >105 136 vs.17 0.553
Hb (gm/dL), ≤12 vs. >12 62 vs.94 0.115
Platelet (103/uL), ≤130 vs. >130 61 vs. 95 0.207
Virologic values
HBV or HCV, (-) vs. (+) 21 vs. 135 0.873
Tumor characters
Tumor size, ≤5 vs. >5 82 vs. 74 0.046*
Tumor numbers, ≤3 vs. >3 65 vs. 91 0.001* 0.009* 0.313 (0.131–0.747)
Intra-hepatic vein, (-) vs. (+) 95 vs. 61 0.661
Extra-hepatic metastases, (-) vs. (+) 81 vs. 75 0.388
Mixed type (vein and metastases), (-) vs. (+) 136 vs. 20 0.517
Therapeutic response
Sorafenib duration, cycle≤ 1 vs. >1 75vs. 81 <0.001* 0.004* 3.694 (1.530–8.920)
TACE (-) vs. (+) 89 vs. 67 0.031* 0.008* 3.197 (1.353–7.553)
Abbreviations: AE adverse event, AST aspartate transaminase, ALT alanine transaminase, Alk-p alkaline phosphatase, AFP alpha-fetoprotein, BMI body mass index
(Cut-off valve: 22 in female and 24 in male), CPC child-pugh classification, Hb hemoglobin, B hepatitis B virus, C hepatitis C virus, INR international normalize ratio,
NBNC non-hepatitis B or C virus, TACE transarterial chemoembolization, WBC white blood cell
*A P-value below 0.05 is considered statistically significant
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Group II; higher BMI (26.35 ± 4.21 versus 22.77 ± 3.77 kg/
m2, p = 0.001), higher Hb (13.04 ± 1.98 versus 11.66 ±
1.70gm/dL, p = 0.019), and lower rate of tumor size <
5 cm (3/15 versus 19/31, p = 0.012) in Group III. After
discontinued sorafenib due to poor response, patients
accepting TACE also presented lower mortality than
those without TACE particularly in total patients (13/
26 versus 67/83, p = 0.001) and Groups I (6/10 versus
24/28, p = 0.001) with II (4/10 versus 23/30, p = 0.034)
(Table 3). Patients accepting TACE had lower AST
(56.16 ± 27.09 versus 97.35 ± 129.26 IU/L, p = 0.008)
than those without TACE among HCC total patients;
lower virology rate (6/10 versus 28/30, p = 0.026) in
Group II; lower Alk-p (81.25 ± 18.66 versus 130.67 ±
64.17 IU/L, p = 0.009), lower average dose (16.04 ±
2.14 versus 20.69 ± 5.83 mg/kg, p = 0.004), and lower
Fig. 2 Kaplan-Meier analysis of sorafenib response (a) and overall survival (b). P-value below 0.05 is considered statistically significant
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cirrhotic rate (3/6 versus 23/25, p = 0.038) in Group
III. No mortality case was induced by TACE.
Discussion
Sorafenib inhibits proliferation and angiogenesis while
promoting apoptosis of tumors [5, 6], and is proven to
prolong survival in advanced HCC cases [8, 9]. As in
earlier studies [8, 9, 21–23], the clinical factors including
superior liver preservation (score 5), lower AFP, or less
aggressive tumor condition remained as the crucial roles
to reflect patient results in our study (Table 2). There-
fore, highly selected patients should be emphasized in
initial sorafenib therapy.
Nevertheless, problems remain in clinical practice, in-
cluding high sorafenib costs that raise economic pres-
sure [13], as well as severe AE rate from 26 to 88 % that
might limit sorafenib dosage and further affect thera-
peutic response [8, 9, 14, 15]. To attain greatest benefit,
we analyzed the relationship of different sorafenib doses
with efficacy. As in previous studies [8, 9], the presence
of AE also played an important role predicting thera-
peutic response. Importantly, patients could tolerate lon-
ger duration (>1 cycles) of obtained therapeutic benefit
from sorafenib (Table 2). Furthermore, we found despite
Groups II and III presenting poorer baseline characteris-
tics than I including lower albumin (3.68 ± 0.51 g/dL
versus 4.05 ± 0.42 g/dL, p < 0.001 respectively) and older
age (64.5 ± 12.02 versus 58.75 ± 13.33 years, p = 0.028
respectively) (Table 1), Groups II and III rather than I
still showed better sorafenib response and survival
benefit (p = 0.010 and p = 0.011 respectively) (Fig. 2) as
our finding of poorer sorafenib response significantly
correlated with higher mortality (r = 0.756, p < 0.001).
This revealed sorafenib, even at lower dosages, could
also provide therapeutic benefit; particularly for patients
tolerating longer sorafenib duration [24]. Accordingly,
this could alleviate economic pressure with tolerable
dose for HCC therapy as well as wastage of medical
resources.
In clinic, combination of TACE with sorafenib has
proven more effective than TACE or sorafenib mono-
therapy for unresectable HCC [17], but no data has
reported on the exploration of the effect of different
sorafenib dose with subsequent TACE during or after
discontinued sorafenib owing to poor response. In
this study, we observed combined TACE promoted
patient’s survival during the period with sorafenib,
which concurred with a previous finding: the sorafe-
nib/TACE combination shows promise as an effective
and tolerable treatment strategy for unresectable pa-
tients with intermediate stage/advanced HCC [17].
The benefit of TACE also appeared in patients after
discontinued sorafenib, particularly in Group II where
lower mortality in TACE cases existed after discon-
tinuation than for those during sorafenib administra-
tion (Tables 2 and 3). This possibility could be
attributed to AE induced by sorafenib, regarded as an
indicator of better therapeutic response presenting
enough anti-tumor concentrations [25, 26]. Therefore,
TACE showed lower benefit during the period with
sorafenib than that without sorafenib. Once tumor in-
hibition with sorafenib significantly decreased due to
poor response and probably induced tumor re-growth,
the effect of TACE became obvious. Group III rather
than I or II presented insignificant benefit from TACE
after discontinued sorafenib, the limited case number
probably contributed to the result, and further larger
studies need to be adopted in the future.
Although median overall survival in our study (7.50 ±
1.44 months) was shorter than SHARP (10.7 months)
[8], better than Asian-Pacific studies (6.5 months)
[9] and probably exceeded the SHARP study: 21 pa-
tients (4 in Group I, 12 in Group II, 5 in Group III)
still accepted sorafenib and 42 cases (10 in Group I,
22 in Group II, 10 in Group III) had survived at end
of follow-up time. Additionally, we correlated body
mass index (kgs/m2) with average sorafenib dose
[mg/(kgs/m2)] and patient’s survival, with no signifi-
cant differences in HCC total cases or separate
groups (Table 2). Even after excluding TACE cases
from the period with sorafenib, higher average dos-
age also could not promote therapeutic response
[31.86 ± 9.54 versus 29.48 ± 9.78 mg/(kgs/m2), p = 0.246]
and prolong survival [31.39 ± 9.73 versus 30.01 ± 9.32 mg/
(kgs/m2), p = 0.581].
Table 3 Comparison of mortality in presence or absence of TACE during and after discontinuation of sorafenib administration
Sorafenib (+) TACE (+) vs. TACE (-) Sorafenib (-) TACE (+) vs. TACE (-)
Subgroups Subgroups
Group I (n = 52) 14/21 vs. 28/31 p = 0.002* Group I (n = 38) 6/10 vs. 24/28 p = 0.001*
Group II (n = 58) 13/21 vs. 23/37 p = 0.595 Group II (n = 40) 4/10 vs. 23/30 p = 0.034*
Group III (n = 46) 12/15 vs. 24/31 p = 0.074 Group III (n = 31) 3/6 vs. 20/25 p = 0.647
HCC-total Patients (N = 156) 39/57 vs. 75/99 p = 0.002* HCC-total Patients (N = 109) 13/26 vs. 67/83 p = 0.001*
Abbreviations: Group I always accepted 800 mg/day; Group II initially accepted 800 mg/day tapering to 400 mg/day owing to adverse events; Group III always
accepted 400 mg/day. TACE transarterial chemoembolization
*A P-value below 0.05 is considered statistically significant
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Conclusions
According to our interpretations, low-dosage sorafe-
nib also provided satisfactory therapeutic result,
which not only appeared tolerable but also lowered
economic pressure and conserved medical resources.
Beside the initial variables including the presence of
AE, superior liver preservation, lower AFP, less ag-
gressive tumor condition, and longer sorafenib dur-
ation benefited patient’s survival, synergic TACE
promoted patient’s survival during the period of
sorafenib administration and also appeared after so-
rafenib discontinuation. Our study provided much
useful information in unresectable HCC patients
with compensated liver disease and venous invasion
or extra-hepatic metastases but was limited in the
size of cohorts; therefore, further larger studies need
to be adopted in the future.
Abbreviations
AE: adverse events; AFP: alpha-fetoprotein; Alk-p: alkaline phosphatase;
ALT: alanine transaminase; AST: aspartate transaminase; CR: complete
response; Cr: creatinine; CT: contrast-enhanced tomography;
CTCAE: common terminology criteria for adverse events; Hb: hemoglobin;
HBV: hepatitis B Virus infection platelet; HCC: hepatocellular carcinoma;
HCV: hepatitis C Virus infection; INR: international normalize ratio;
NCI: National Cancer Institute; PR: partial response; RECIST: response
evaluation criteria in solid tumors criteria; SD: stable disease;
TACE: transarterial chemoembolization; WBC: white blood cell.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
J-TK and W-DH involved in the study design, as well as in the planning, con-
ducting, collecting and interpreting of data for this study, and in drafting/
editing the manuscript. C-YP involved in the planning, collection and inter-
pretation of data for this study, and in drafting the manuscript. P-HC and H-
CL involved in data collection and drafting/editing of the manuscript. K-SC,
J-WC, Y-YC, C-J, C-LF, W-PS, and S-HC involved in data collection. All the
above-mentioned authors have approved the final draft submitted.
Acknowledgements
All procedures met ethical standards of the responsible committee on
human experimentation (institutional and national) and with the 1975
Helsinki Declaration, as revised in 2008. The Institutional Review Board of
China Medical University Hospital also approved this retrospective study
(CMUH103-REC2-147). Importantly, heartfelt thanks to participants, as well as
research assistants of the Liver Unit for technical assistance in data collection
and case enrollment.
Received: 27 October 2015 Accepted: 15 April 2016
References
1. Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, et al. Global
Cancer Facts and Figures. 2007. https://www.cancer.org/acs/groups/
content/@nho/documents/document/globalfactsandfigures2007rev2p.pdf.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update.
Hepatology. 2011;53:1020–2.
3. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging
and treatment: BCLC update and future prospects. Semin Liver Dis.
2010;30:61–74.
4. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et
al. Risk factors contributing to early and late phase intrahepatic recurrence
of hepatocellular carcinoma after hepatectomy. J Hepatol.
2003;38:200–7.
5. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al.
BAY 43-9006 exhibits broad-spectrum oral antitumor activity and
targets the RAF/MEK/ERK pathway and receptor tyrosine kinases
involved in tumor progression and angiogenesis. Cancer Res.
2004;64:7099–109.
6. Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, et al. Sorafenib
(BAY 43-9006) inhibits tumor growth and vascularization and induces tumor
apoptosis and hypoxia in RCC xenograft models. Cancer Chemother
Pharmacol. 2007;59:561–74.
7. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol.
2004;41:864–80.
8. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al.
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med.
2008;359:378–90.
9. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced hepatocellular
carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Lancet Oncol. 2009;10:25–34.
10. Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara A, et al.
Activation of mitogen-activated protein kinases/extracellular signal-
regulated kinases in human hepatocellular carcinoma. Hepatology.
1998;27:951–8.
11. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H,
et al. Asian Pacific Association for the Study of the Liver consensus
recommendations on hepatocellular carcinoma. Hepatol Int.
2010;4:439–74.
12. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS. Ubiquitous
activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology.
2006;130:1117–28.
13. Carr BI, Carroll S, Muszbek N, Gondek K. Economic evaluation of sorafenib
in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol.
2010;25:1739–46.
14. Ogasawara S, Kanai F, Obi S, Sato S, Yamaguchi T, Azemoto R, et al. Safety
and tolerance of sorafenib in Japanese patients with advanced
hepatocellular carcinoma. Hepatol Int. 2011;5:850–6.
15. Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, et al. Phase III
study of sorafenib after transarterial chemoembolisation in Japanese and
Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer.
2011;47:2117–27.
16. Alsaied OA, Sangwan V, Banerjee S, Krosch TC, Chugh R, Saluja A, et al.
Sorafenib and triptolide as combination therapy for hepatocellular
carcinoma. Surgery. 2014;156:270–9.
17. Abdel-Rahman O, Elsayed ZA. Combination Trans Arterial
Chemoembolization (TACE) Plus Sorafenib for the Management of
Unresectable Hepatocellular Carcinoma: A Systematic Review of the
Literature. Dig Dis Sci. 2013;58:3389–96.
18. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R.
Transection of the oesophagus for bleeding oesophageal varices.
Br J Surg. 1973;60:646–9.
19. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.
0: development of a comprehensive grading system for the adverse effects
of cancer treatment. Semin Radiat Oncol. 2003;13:176–81.
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et
al. New guidelines to evaluate the response to treatment in solid tumors.
European Organization for Research and Treatment of Cancer, National
Cancer Institute of the United States, National Cancer Institute of Canada. J
Natl Cancer Inst. 2000;92:205–16.
21. Changchien CS, Chen CL, Yen YH, Wang JH, Hu TH, Lee CM, et al.
Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan:
prognostic features, treatment outcome, and survival. J Gastroenterol.
2008;43:159–70.
22. Carr BI, Pancoska P, Branch RA. Tumor and liver determinants of prognosis
in unresectable hepatocellular carcinoma: a large case cohort study. Hepatol
Int. 2009;4:396–405.
23. Bouattour M, Payancé A, Wassermann J. Evaluation of antiangiogenic
efficacy in advanced hepatocellular carcinoma: Biomarkers and functional
imaging. World J Hepatol. 2015;7:2245–63.
24. Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, et
al. Is intra-patient sorafenib dose re-escalation safe and tolerable in
patients with advanced hepatocellular carcinoma? Int J Clin Oncol.
2014;19:1029–36.
Hsiao et al. BMC Gastroenterology  (2016) 16:50 Page 8 of 9
25. Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L, et al.
Early Skin Toxicity as a Predictive Factor for Tumor Control in
Hepatocellular Carcinoma Patients Treated with Sorafenib. Oncologist.
2010;15:85–92.
26. Arrondeau J, Mir O, Boudou-Rouquette P, Coriat R, Ropert S, Dumas G, et al.
Sorafenib exposure decreases over time in patients with hepatocellular
carcinoma. Invest New Drugs. 2012;30:2046–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Hsiao et al. BMC Gastroenterology  (2016) 16:50 Page 9 of 9
